There is a national movement to institute an Insulin Co-Pay Cap. If this legislation passes the senate, there would be a $35/ month limit on individuals' share for insulin. Although this will help reduce the cost burden for persons on insulin, this will mean that employers will be responsible for the remaining cost. There is hope that this will drive down PBM/Manufacturer pricing for insulin, but there is also concern that commercial payors will be paying more for these medications since the government will negotiate more appropriate rates.
In Q1 2022, we will be editing our diabetes reporting to separate Type 1 from Type 2 Diabetes since the care strategies are very different. We will also provide reporting based on insulin use and plan vs. member paid and monitoring the cost of insulin to the plan and provide any updated strategies.